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Mice injected with syngeneic or semisyngeneic tumor cell lines eventually succumb 
to the tumor despite the presence of tumor specific  antigens  (TSA)  on most tumors 
which have been examined  (1).  Attempts to explain  this phenomenon have usually 
employed hard  experimental  evidence which has detected  the existence of blocking 
antibodies  (1),  soluble  TSA (2),  and complexes of TSA and blocking antibodies  (3), 
all  of which result  in  the  eliciting  of weak  immune  responses  against  tumor cells. 
Recently an additional  explanation has been suggested  (4, 5)  which postulates  that 
the induction of an antilymphocytic autoimmune process by tumor cells would seri- 
ously impair  immunosurveillance  capabilities.  In  the  first  paper  of this  series,  we 
reported the finding of vigorous immune reactivity by immunocompetent cells  from 
tumor-bearing FI mice against normal parental  cells  of the  strain  from which  the 
tumor was derived. 
The purpose of the present work was twofold: (a)  to study autoimmune-like 
processes of this type in a  completely syngeneic system, and (b) to examine the 
strength and the nature of the cellular immune reactions provoked or produced 
by syngeneic or semisyngeneic mouse tumor cells. 
Materials and Methods 
M/ce.--Mice of the inbred strains DBA/2 (H-2  d) and BDF 1, which is the hybrid of DBA/2 
and C57B1/6 (H-2b), were obtained from Jackson Laboratories, Bar Harbor, Maine. 
Tumor Cell Line.--L1210 leukemia was routinely maintained  in BDFx mice as previously 
described (5) and was transferred to DBA/2 mice in some of these experiments. The L1210 leu- 
kemia is of DBA/2 origin. 
Mixed Lymphocyte Reactions (MLR's).---Cultures were set up and results compiled as pre- 
viously described (5). 
RESULTS 
Spleen cells were collected from DBA/2 mice which had been inoculated with 
L1210 leukemia  cells  7 days earlier  (DBAt).  When DBAt cells were cultured 
with  normal  DBA/2  cells  in  a  two-way MLR,  a  vigorous immune  reaction 
occurred  (Table  I,  experiment  33).  In  order  to  determine  the  cell  type  re- 
sponsible  for this activity,  DBA/2  or DBAt cells  were pretreated  with  mito- 
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mycin C before culture (Table I, experiments 34 and 43). Normal DBA/2 cells 
reacted weakly or not at all  to mitomycin-treated DBAt cells. On the other 
hand,  significant  immune reactivity by DBAt cells against mitomycin-treated 
normal DBA/2 cells was noted. This suggestive antiself reactivity occurs only 
in the DBAt spleen cell population since normal DBA/2 cells do not respond to 
syngeneic DBA/2  cells  (Table  II,  experiment  27).  It  is  apparent  that  th~s 
activity is at least induced if not produced by the tumor cells. 
Ascitic cells from L1210-bearing  mice were also found to be capable of re- 
sponding significantly  to normal DBA/2 cells  (Table II,  experiments 29 an~d 
TABLE  I 
Mixed Lymphocyte Reactions of DBA/Z Spleen Cells from LlglO-Bearing Mice and Normal 
Syngene~ DB  A ] Z Spleen Cells 
Experi- 
ment 
no. 
33 
34 
43 
DBA/2 
1750 
2790 
2790 
3280 
3280 
DPM 
DBA/2m* 
450 
588 
588 
DBAt~ 
7687 
4563 
4563 
6455 
6455 
DBAtm*,~t 
478 
2033 
2033 
MLR 
174,996 
122,332 
3,478 
16,906 
78,090 
11,547 
54,888 
4,351 
Combination 
DBA/2 X  DBAt 
DBA/2 X  DBAt 
DBA/2 X  DBAtm 
DBAt X  DBA/2m 
DBA/2 X  DBAt 
DBA/2 X  DBAtm 
DBA/t X  DBA/2m 
DBAtm X  DBA/2m 
R§ 
18.5 
16.6 
1.1 
3.4 
8.0 
2.2 
7.8 
1.6 
*  Mitomycin-treated spleen  cells. 
~; Spleen  cells from L1210-bearing DBA/2 mice. 
§ DPM in mixed cultures divided by sum of DPM in cultures of one cell type alone. 
Ex- 
peri-] 
ment 
no. 
24¶ 
36 
24-1 
28 
24-2 
27 
27 
29 
36 
DBA 
6,324 
1,722 
1,722 
TABLE  II 
Mixed Lymphocyte Reactions of Normal and Mal~ 
DPM 
DBAm* 
1,150 
1,064 
618 
BDF 
3638 
768 
BDFt~ 
127,390 
5,934 
L121O§ 
253,020 
97,274 
L1210m* 
45,702 
4,622 
45,702 
6,941 
45,702 
38,541 
MLR 
11,368 
3,313 
311,332 
37,653 
220,057 
73,888 
3,058 
559,507 
383,576 
nant  Cells 
Combination 
BDF  X  L1210m 
BDF  X  L1210m 
BDFt  X  L1210m 
BDFt  X  L1210m 
DBA vs. Ll210m 
DBA X  L1210m 
DBA X  DBAm 
L1210 vs. DBAm 
L1210 vs. DBAm 
Rll 
<1 
<1 
1.8 
2.9 
4.2 
1.8 
1.1 
2.2 
3.9 
* Mitomycin-treated cells. 
Spleen  cells from L1210-bearlng BDF1 mice. 
§ Ascitic L1210 cells from BDF1 mice. 
H  DPM in mixed cultures divided by the sum of DPM in cultures of one cell type alone. 
¶ Experiments no. 24, 24-1, and 24-2 were all done at the same time using the same pools of cells. 232  TUMOR  INDUCTION  OF  AUTOIM~UNE-LIKE  ACTIVITY 
36). Both the spleen cell population and the ascitic cell population have been 
reported to consist almost entirely of malignant cells (6). However, since there 
are some normal cells present in each case, it is not possible to determine as yet 
which cell type (normal or malignant) is reacting against the normal syngeneic 
cells. It is also important to note that there are differences, both morphological 
(6) and physiological, between splenic L1210 cells and ascitic L1210 cells. The 
ascitic L1210 cells  usually take up much more [ZH]thymidine when cultured 
alone than do splenic L1210 cells. Also, spleen cells from tumor-bearing Fi mice 
(BDFt) were able to respond significantly  in MLR to ascitic L1210 cells (Table 
II,  experiments  24-1 and  28).  One possible  explanation for  the  latter  phe- 
nomenon might be that it is the few remaining normal cells in the BDFt spleen 
cell population which are responding to the presumed TSA on the ascific L1210 
cells. However, this may not be the case since normal BDF1 cells do not respond 
significantly to ascitic L1210 cells  (Table II, experiments 24 and 36).  Normal 
DBA/2 spleen cells, on the other hand, do respond significantly to mitomycin- 
treated L1210 cells  (Table II, experiments 24-2 and 27). Another immunologic 
difference is also evident between splenic and ascitic L1210 cells. Normal BDF1 
mice, which did not respond to L1210m (Table II), did respond significantly to 
mitomycin-treated splenic L1210 cells, i.e., BDFtm (Table III, experiments 27, 
29  and 32).  Also interesting in this regard was  the finding that BDFt cells, 
which responded very vigorously to mitomycin-treated DBA/2  cells  (5),  did 
not respond at all to normal mitomycin-treated BDFI cells  (Table III). Pos- 
sibly, the presence of C57B 1/6 antigens on BDFi cells interferes with the recog- 
nition of the DBA/2 antigens also present on the FI cells. Alternatively, antigen 
density on the membranes of the F1 cells may be limiting in this case (7). 
DISCUSSION 
The data reported in this paper, in which spleen cells obtained from mice- 
bearing syngeneic tumors react against normal syngeneic cells,  do not neces- 
TABLE III 
Mixed Lymphocyte Reactions of BDFt and Normal BDFi Cells 
Experiment  DPM  Combination  R§ 
no.  BDF  BDFm*  BDFt:~  BDFtm  MLR 
27[I  995  7,136  23,571  BDF  M  BDFt  2.9 
27-1  995  3,928  10,526  BDF  M  BDFtm  2.1 
29  2,800  3,058  19,396  BDF  X  BDFtm  3.3 
32~"  1,794  3,727  9,695  BDF  X  BDFtm  1.8 
32-1  465  21,963  13,837  BDFt  X  BDFm  <I 
36  213  5,468  5,076  BDFt  M  BDFm  <1 
32-2  1,794  3,676  BDF  M  BDF  1.0 
* Mitomycin-treated  cells. 
:~ Spleen  cells from L1210  bearing mice. 
§ DPM in mixed cultures  divided by sum of DPM in cultures  of one cell type alone. 
]I Experiments 27 and 27-1 were done at the same time using ~he same pools of cells. 
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sarily imply that an autoimmune reaction is occurring in the tumor-bearing 
mice. Only the reaction of DBAt cells against autologous lymphocytes would 
constitute a definite autoimmune process. For this reason, we chose to refer to 
the present data as representing an autoimmune-like process, which strongly 
suggests that spleen cells from tumor-bearing mice are able to induce cellular 
antilymphocytic autoimmunity in host animals. Definitive proof of this sugges- 
tion might provide another interpretation for the failure of the immunosurveil- 
lance mechanism in mice which succumb to lymphocytic tumors. It might also, 
hopefully, provide impetus for attempting to find a  similar autoimnmne reaco 
tivity  in  human  cancer  patients.  Such  phenomena  have  been  reported  in 
patients with Hodgkin's disease (8), some of whom at least develop antilympho- 
cyfic cytotoxic antibodies. However, if cellular immune activity of this sort is 
confined to splenic lymphocytes, detection of such activity  would involve serious 
technical difficulties with human patients.  Repetition of the experiments re- 
ported in this paper on human subjects would require the use of splenic lympho- 
cytes from human patients who are identical twins, or at least identically typed 
siblings, one of whom had a malignant lymphocytic disease. 
The reaction of DBAt cells  against normal DBA/2 cells demonstrates that 
lymphocytes capable of reacting to self determinants do exist. It is not clear 
whether the reactive lymphocytes are normal or malignant cells. Burnet (9) in 
his clonal selection hypothesis suggests that all immunocytes capable of reacting 
to self are destroyed. It is known, however, that acquired tolerance to an antigen 
can be broken by the use of cross-reacting antigens (10) or by chemically altered 
antigens, i.e., by adding certain haptenic groups to the protein carrier (11-13); 
These results might offer an explanation for our findings if we make several 
assumptions: (a) that it is the few remaining normal cells present in the DBAt 
spleens which are causing the reaction against syngeneic cells and (b) that TSA 
on the malignant cells act as haptens and the normal histocompatibility anti- 
gens act as carriers, i.e., the normal cells in the tumor-bearing spleens,  during 
their reactions against the malignant cells (hapten +  carrier) would be induced 
into reacting against normal DBA/2 cells  (carrier). However, it is not known 
if tolerance in cellular immune systems can be broken in the same manner as it is 
in the humoral systems alluded to above. Such a mechanism would not be sur  -, 
prising, however, in view of the fact that delayed hypersensitivity reactions are 
carrier specific  (14-17). 
Interpretation of results dealing with the immunobiology of transplantable 
tumors is fraught with danger, since some of these tumor cell lines are known to 
undergo remarkable changes during passage (18). For'this reason and for other 
reasons which will become apparent below, there may be at least three alterna- 
tive explanations for our findings: (a)  perhaps  the phenomena of "antigenic 
simplification" or  "antigenic modulation" are  active  in  the  system studied 
here. Malignant cells which have been passaged in vivo are kncJwn to undergo 
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are no longer restricted to a specific strain, presumably because they have lost 
some or all of their 1t-2 antigens (18, 19). Also, it has been demonstrated that 
the exposure of living cells to antibodies against cell surface antigens may lead 
to the specific disappearance of these antigens (20) by the process of pinocytosis 
(21), i.e., antigenic modulation. The possibility exists, therefore, that the L1210 
tumor cell  line used in these experiments had lost its original tt-2  d antigens. 
This  loss,  if accompanied by appropriate  karyotypic changes,  might  enable 
the DBAt cells  or the ascitic L1210 cells  to  recognize the//-2  g antigens on 
normal DBA/2 cells as foreign, and thus cause the response seen in the present 
experiments. A similar theory was proposed by Tyler to explain the origin and 
development of lymphoid neoplasms  (22).  Tyler  theorized  that malignancy 
developed when a normal cell lost one or more histocompatibility antigens. All 
normal cells would then be antigenic to the mutated cell and would therefore 
provide a  constant stimulus for unrestrained growth leading to a  lymphoid 
neoplasm. The L1210 cells used in the present experiments have been passaged 
in this laboratory for 3 yr in BDF1 mice, and it is not known what effects this 
passage may have had on the expression  of the histocompatibility antigens or 
genomes of the L1210 cells.  However, it must be pointed out that "antigenic 
simplification" does not seem to have occurred in our L1210 line. It will only 
grow in BDFI or DBA/2  animals and is rejected when transferred to  either 
C57B1/6  or  CBA/J  mice  (unpublished  observations).  (b)  Another  possible 
explanation for our data is suggested by experiments in which oncogenic viruses 
were found to be activated during graft vs. host (GVH) reactions (23). Viruses 
also appeared in MLR of parental and F1 cells but not when either lymphocyte 
population was  incubated by itself  (24).  However,  when lymphocyte trans- 
formation was blocked by treatment of parental cells with mitomycin C, virus 
activation did not occur. Perhaps in the system studied here oncogenic viruses 
are  liberated and lead to increased uptake of [3H]thymidine by the reacting 
cells. However, since in this system and the one reported earlier (5) the normal 
DBA/2  cells  were pretreated with mitomycin C, and since the reacting cells 
might be malignant cells, such an explanation may not be valid. Also, the pres- 
ence of viruses is known to inhibit MLR's (25).  (c) It has recently been shown 
that thymocytes from certain strains of newborn mice will react significantly 
in MLR against syngeneic lymphocytes (26).  Reactivity is lost in thymocytes 
from older mice. It could be postulated that DBAt cells  or BDFt cells  have 
reverted to a neonatal condition and are thus able to mount an immune reaction 
against syngeneic cells.  It has also been determined that lymphocytes from 
lymph nodes of rats sensitized in vitro to autochthonous or syngeneic cells were 
able to cause a GVHR in syngeneic hosts (27). These results suggest that cells 
capable of reacting against self do exist but are inhibited by factors present in 
fresh serum (27).  The present work, in this paper, indicates that cells capable 
of reacting to self are either induced or produced by the L1210 leukemia. 
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that it might suggest an explanation for the peculiar wasting process undergone 
by animals and human patients with various types of malignancies. On  the 
surface, at least, a striking similarity exists between the cachexia exhibited by 
some cancer patients and the wasting syndrome of graft vs. host disease (22). 
In  the  latter  case,  the  wasting process  is  the pathological manifestation of 
GVHR. One could assume that a GVHR is occurring in the DBAt spleen since 
DBAt cells react in MLR (the in vitro equivalent of GVHR [28]) with normal 
DBA/2 cells. In this case, however, both the host and the graft would be DBA/2 
cells. Since the L1210 injected animals survive for only 7-10 days, it is impos- 
sible to determine if they are wasting. The spleens of these animals are always 
enlarged, but this effect is probably due to increased numbers of tumor cells in 
the splenic tissue. Interesting in this regard is the finding of a high incidence of 
malignant lymphomas which occurred in mice undergoing a  chronic GVHR 
(29).  Similarly, reovirus 3 has been reported to transform mouse cells which, 
when injected into newborn animals, cause runting--leading in some cases to 
lymphomas (30). However, a recent attempt to find a significant autoimmune 
process in GVHR failed (31). Nor was any significant GVHR evoked by spleen 
cells  from BALB/c mice bearing a  testicular tumor when injected into syn- 
geneic recipients  (32).  On the other hand, the detection of antinuclear anti- 
bodies which react with syngeneic nuclei has been reported in mice injected 
with parental cells  (33).  The possibility remains, therefore, that some human 
cancer patients may react similarly to the tumor-bearing mice in these experi- 
ments, i.e., some of their immune cells  (splenic lymphocytes?) become capable 
of reacting against self with subsequent impairment of antitumor effectiveness. 
SUMMARY 
A possible consequence of an antilymphocytic autoimmune process would be 
serious impairment of an animal's ability to destroy tumor cells. One measure 
of autoimmune reactivity of this type would be the demonstration of cellular 
immune responsiveness by cells  from tumor-bearing mice against  syngeneic 
normal cells. These experiments demonstrate that spleen cells from mice bearing 
a  lymphocytic  leukemia  of  identical  histocompatability  type  as  the  host 
mounted a vigorous immune response against normal syngeneic cells in a mixed 
lymphocyte reaction  (MLR). Moreover,  ascitic cells  from leukemic mice re- 
sponded significantly to normal syngeneic spleen cells in MLR's. The former 
reactions are  usually much more vigorous than  the  responses  of normal  to 
malignant cells. These results are discussed in terms of the relationship between 
autoimmunity and  neoplasia.  Alternative  explanations  necessitated  by  the 
dangers involved in  the interpretation of the immunology of transplantable 
tumors are considered. 
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